|
業務類別
|
Biotechnology |
|
業務概覽
|
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials. |
| 公司地址
| 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806 |
| 電話號碼
| +1 256 327-9630 |
| 傳真號碼
| +1 510 671-8619 |
| 公司網頁
| https://www.serinatherapeutics.com |
| 員工數量
| 16 |
| Mr. Steven Ledger |
Director and Chief Executive Officer |
美元 450.00K |
27/04/2026 |
| Dr. Srini Tenjarla, PhD |
Senior Vice President, CMC and Formulation; Chief Technology Officer, Subsidiary |
美元 375.00K |
21/04/2026 |
| Mr. Gregory S. Curhan |
Chief Financial Officer and Principal Accounting Officer |
-- |
27/04/2026 |
| Dr. Randall W. Moreadith,M.D.,PhD |
Chief Development Officer |
美元 425.00K |
27/04/2026 |
|
|
| Dr. Gregory Hugh Bailey, M.D. |
Co-Chairman of the Board |
23/03/2026 |
| Dr. Stephen Brannan, M.D. |
Independent Director |
27/04/2026 |
| Mr. Steven Ledger |
Director and Chief Executive Officer |
27/04/2026 |
| Dr. Richard Marshall, C.B.E.,M.D.,PhD |
Independent Director |
27/04/2026 |
| Dr. Balkrishan Gill, PhD |
Executive Co-Chairman of the Board |
23/03/2026 |
| Ms. Karen J. Wilson |
Independent Director |
27/04/2026 |
| Dr. Jay R. Venkatesan, M.D. |
Independent Director |
27/04/2026 |
|
|
|
|
